2001
Hypermutability to ionizing radiation in mismatch repair-deficient, Pms2 knockout mice.
Xu X, Narayanan L, Dunklee B, Liskay R, Glazer P. Hypermutability to ionizing radiation in mismatch repair-deficient, Pms2 knockout mice. Cancer Research 2001, 61: 3775-80. PMID: 11325851.Peer-Reviewed Original ResearchConceptsMismatch repairSimple sequence repeatsWild-type transgenic miceCell linesLambda cII geneMutation frequencyDNA mismatch repairHigher clonogenic survivalMMR-deficient miceLambda shuttle vectorTolerance phenotypeSequence repeatsPatterns of IRReporter geneRepeat sequencesMononucleotide repeat sequencesShuttle vectorSingle bp deletionCII geneNullizygous animalsNullizygous miceHypermutabilityBp deletionWild-type miceClonogenic survival
2000
Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation
Turner B, Gumbs A, Carter D, Glazer P, Haffty B. Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. International Journal Of Radiation Oncology • Biology • Physics 2000, 47: 1169-1176. PMID: 10889369, DOI: 10.1016/s0360-3016(00)00525-3.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceBreast cancer patientsDistant disease-free survivalCancer patientsRadiation therapyOverall survivalEarly-stage breast cancer patientsEarly breast cancer recurrenceAxillary lymph node involvementCycD1 expressionTotal median doseBreast tumor recurrenceDisease-free survivalLymph node involvementBreast cancer populationBreast cancer recurrenceBreast tumor relapseCyclin D1 expressionCyclin D1 levelsMedian doseNode involvementMetastatic diseaseLate relapsePrognostic significancePatient populationPrognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiation
Yoo S, Carter D, Turner B, Sasaki C, Son Y, Wilson L, Glazer P, Haffty B. Prognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiation. International Journal Of Cancer 2000, 90: 22-28. PMID: 10725854, DOI: 10.1002/(sici)1097-0215(20000220)90:1<22::aid-ijc3>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsEarly-stage larynx cancerLocal relapsePrognostic significanceLarynx cancerTotal median dosePrimary radiation therapySquamous cell carcinomaCell nuclear antigen levelsParaffin-embedded specimensSignificant clinical implicationsCase-control designPercent distributionLarynx cancer patientsCyclin D1 protein levelsCyclin D1 levelsMedian doseControl patientsLocal recurrenceAntigen levelsCancer patientsCell carcinomaDaily fractionsRadiation therapyIndex caseClinical information
1999
BRCA1/BRCA2 in breast-conserving therapy.
Turner B, Glazer P, Haffty B. BRCA1/BRCA2 in breast-conserving therapy. Journal Of Clinical Oncology 1999, 17: 3689. PMID: 10550169.Peer-Reviewed Original ResearchBRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.
Turner B, Harrold E, Matloff E, Smith T, Gumbs A, Beinfield M, Ward B, Skolnick M, Glazer P, Thomas A, Haffty B. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. Journal Of Clinical Oncology 1999, 17: 3017-24. PMID: 10506595, DOI: 10.1200/jco.1999.17.10.3017.Peer-Reviewed Original ResearchConceptsBreast cancer patientsDeleterious BRCA1/2 mutationsCancer patientsBRCA1/2 mutationsControl patientsAge 40BRCA2 mutationsRadiation therapyControl breast cancer patientsNew primary breast cancerRecurrent breast cancer patientsEarly-onset breast cancer patientsBRCA1/BRCA2 mutationsBreast-conserving managementBreast-conserving therapySecond primary tumorsPrimary breast cancerOutcome of treatmentBRCA2 germline mutationsBRCA1/BRCA2 germline mutationsSalvage mastectomySystemic progressionLocal relapseMedian timeRecurrent cancerDifferent mutator phenotypes in Mlh1- versus Pms2-deficient mice
Yao X, Buermeyer A, Narayanan L, Tran D, Baker S, Prolla T, Glazer P, Liskay R, Arnheim N. Different mutator phenotypes in Mlh1- versus Pms2-deficient mice. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 6850-6855. PMID: 10359802, PMCID: PMC22005, DOI: 10.1073/pnas.96.12.6850.Peer-Reviewed Original ResearchConceptsMismatch repairMutator phenotypeMutation rateDifferent chromosomal locationsSingle-molecule PCRDinucleotide repeat lociMutation frequencyDNA mismatch repairMononucleotide repeat tractsChromosomal locationCellular processesDNA repair capacityHigh mutation frequencyDifferent mutator phenotypesMultiple genetic alterationsKnockout strainRepeat tractMlh1pMLH1 MMR geneRepeat lociGenetic alterationsDifferent tumor spectrumRepair capacityTumor developmentMMR genes